FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1981210662> ?p ?o ?g. }

• W1981210662 endingPage "287" @default.
• W1981210662 startingPage "274" @default.
• W1981210662 abstract "This article reviews the available information on pregabalin, a new anticonvulsant for peripheral neuropathic pain. Pregabalin was provisionally approved by the US Food and Drug Administration in December 2004 and was granted final approval after controlled substance scheduling (Schedule V) by the US Drug Enforcement Agency in August 2005. A MEDLINE search (1986-August 2005) was conducted to identify pertinent studies in the Englishlanguage. The search terms included pregabalin, PD144723, CI-1008, gabapentin, and neuropathic pain. Additional references were obtained from the bibliographies of identified articles. All studies that evaluated any aspect of pregabalin in vitro or in vivo in animals or humans were included, with a focus on data relevant to older adults. In preclinical studies, pregabalin, a structural congener of gabapentin, exhibited antinociceptive activity in animal models of neuropathic and inflammatory pain. Unlike gabapentin, pregabalin was well absorbed (>90%), and its absorption was dose independent. Like gabapentin, pregabalin was predominantly excreted unchanged in the urine (⩾98%). Dosed at SO to 200 mg TID, pregabalin was superior to placebo in relieving pain and improving sleep and health-related quality of life in patients with diabetic peripheral neuropathy and postherpetic neuralgia (P < 0.001-P < 0.049). No active-controlled trials were available. The most problematic adverse events associated with pregabalin were dizziness and somnolence (21%26%). In the absence of active-controlled clinical trials and geriatric-specific efficacy/tolerability data, theplace of pregabalin in the analgesic armamentarium for the elderly is unclear. Because pregabalin is a Schedule V controlled substance, its utility is not compromised by substantial limitation of access or the need for extra steps in prescribing. However, abuse potential is a consideration, and utilization should be carefully monitored, particularly in patients with a past or current history of substance abuse. The improved pharmacokinetic profile of pregabalin relative to gabapentin is manifested in linear and dose-independent absorption and a narrow therapeutic dosing range. However, pregabalin still requires multiple administrations per day, and daily doses >150 mg/d require dose titration. The relatively high frequency of central nervous system adverse events, particularly dizziness and somnolence, is a concern in the elderly. Time and further experience should clarify the role of this agent." @default.
• W1981210662 created "2016-06-24" @default.
• W1981210662 creator A5020501067 @default.
• W1981210662 date "2005-12-01" @default.
• W1981210662 modified "2023-10-01" @default.
• W1981210662 title "Pregabalin in neuropathic pain: A more “pharmaceutically elegant” gabapentin?" @default.
• W1981210662 cites W1569947967 @default.
• W1981210662 cites W1594153838 @default.
• W1981210662 cites W1965693537 @default.
• W1981210662 cites W1969313589 @default.
• W1981210662 cites W1970097416 @default.
• W1981210662 cites W1972387365 @default.
• W1981210662 cites W1977042570 @default.
• W1981210662 cites W1978678518 @default.
• W1981210662 cites W1981136766 @default.
• W1981210662 cites W1981435820 @default.
• W1981210662 cites W1981480712 @default.
• W1981210662 cites W1992436256 @default.
• W1981210662 cites W1997048153 @default.
• W1981210662 cites W2006085261 @default.
• W1981210662 cites W2008662383 @default.
• W1981210662 cites W2011913908 @default.
• W1981210662 cites W2016027137 @default.
• W1981210662 cites W2019891586 @default.
• W1981210662 cites W2020591098 @default.
• W1981210662 cites W2021532501 @default.
• W1981210662 cites W2027053525 @default.
• W1981210662 cites W2031004040 @default.
• W1981210662 cites W2031489310 @default.
• W1981210662 cites W2033644828 @default.
• W1981210662 cites W2034471525 @default.
• W1981210662 cites W2034930462 @default.
• W1981210662 cites W2043135461 @default.
• W1981210662 cites W2043987721 @default.
• W1981210662 cites W2054260401 @default.
• W1981210662 cites W2055427394 @default.
• W1981210662 cites W2068047216 @default.
• W1981210662 cites W2068602147 @default.
• W1981210662 cites W2070246197 @default.
• W1981210662 cites W2071419929 @default.
• W1981210662 cites W2076516150 @default.
• W1981210662 cites W2082940913 @default.
• W1981210662 cites W2084174148 @default.
• W1981210662 cites W2103289578 @default.
• W1981210662 cites W2107046566 @default.
• W1981210662 cites W2109047274 @default.
• W1981210662 cites W2119931634 @default.
• W1981210662 cites W2120647108 @default.
• W1981210662 cites W2159977024 @default.
• W1981210662 cites W2160269874 @default.
• W1981210662 cites W2170481173 @default.
• W1981210662 cites W2949515790 @default.
• W1981210662 cites W4246062575 @default.
• W1981210662 cites W73170440 @default.
• W1981210662 cites W99098873 @default.
• W1981210662 doi "https://doi.org/10.1016/j.amjopharm.2005.12.008" @default.
• W1981210662 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16503325" @default.
• W1981210662 hasPublicationYear "2005" @default.
• W1981210662 type Work @default.
• W1981210662 sameAs 1981210662 @default.
• W1981210662 citedByCount "141" @default.
• W1981210662 countsByYear W19812106622012 @default.
• W1981210662 countsByYear W19812106622013 @default.
• W1981210662 countsByYear W19812106622014 @default.
• W1981210662 countsByYear W19812106622015 @default.
• W1981210662 countsByYear W19812106622016 @default.
• W1981210662 countsByYear W19812106622017 @default.
• W1981210662 countsByYear W19812106622018 @default.
• W1981210662 countsByYear W19812106622019 @default.
• W1981210662 countsByYear W19812106622020 @default.
• W1981210662 countsByYear W19812106622021 @default.
• W1981210662 countsByYear W19812106622022 @default.
• W1981210662 countsByYear W19812106622023 @default.
• W1981210662 crossrefType "journal-article" @default.
• W1981210662 hasAuthorship W1981210662A5020501067 @default.
• W1981210662 hasConcept C142724271 @default.
• W1981210662 hasConcept C197934379 @default.
• W1981210662 hasConcept C204787440 @default.
• W1981210662 hasConcept C2776468701 @default.
• W1981210662 hasConcept C2776608144 @default.
• W1981210662 hasConcept C2777107010 @default.
• W1981210662 hasConcept C2778375690 @default.
• W1981210662 hasConcept C2778866549 @default.
• W1981210662 hasConcept C2780820201 @default.
• W1981210662 hasConcept C42219234 @default.
• W1981210662 hasConcept C71924100 @default.
• W1981210662 hasConcept C98274493 @default.
• W1981210662 hasConceptScore W1981210662C142724271 @default.
• W1981210662 hasConceptScore W1981210662C197934379 @default.
• W1981210662 hasConceptScore W1981210662C204787440 @default.
• W1981210662 hasConceptScore W1981210662C2776468701 @default.
• W1981210662 hasConceptScore W1981210662C2776608144 @default.
• W1981210662 hasConceptScore W1981210662C2777107010 @default.
• W1981210662 hasConceptScore W1981210662C2778375690 @default.
• W1981210662 hasConceptScore W1981210662C2778866549 @default.
• W1981210662 hasConceptScore W1981210662C2780820201 @default.
• W1981210662 hasConceptScore W1981210662C42219234 @default.
• W1981210662 hasConceptScore W1981210662C71924100 @default.

• next